General Oncology
Burlington
About General Oncology
General Oncology is developing a pipeline of treatments for solid metastatic cancers and cancers of the blood. They have a clinical trial underway for an investigational treatment for BRCA-related metastatic pancreatic cancer. General Oncology is sponsoring a clinical trial (Clinical Trial GO-1) for its investigational treatment for BRCA-related metastatic pancreatic cancer. The treatment involves two cycles of chemotherapy using melphalan, BCNU, vitamin B12b, and vitamin C, along with two stem cell transplants to reverse bone marrow suppression. The trial is currently open for enrollment.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $42.0M
- Last round: Series Unknown (Jun 2019)
- Website: generaloncology.com
- Phone: 617-468-4646
Industries & Categories
Health Care, Medical, Oncology, Wellness
Social Profiles
Canonical: https://fsome.com/organization/general-oncology-124879 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.